Roche and Ionis Report Phase 3 Proteinuria Win for Sefaxersen in IgA Nephropathy
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
FDA approved FILSPARI for FSGS kidney disease, showing it lowers protein in urine and slows damage. It offers a new treatment option for patients with few choices.
FDA delays approval decision for Filspari in rare kidney disease FSGS until April 2026. Travere Therapeutics (TVTX) continues commercial preparations for potential first FSGS treatment.
Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.
FDA confirms proteinuria reduction as valid FSGS approval endpoint in Dimerix feedback, boosting confidence in Travere Therapeutics' upcoming Filspari decision.